SCHEMBL3433495

SCHEMBL3433495

CC(C)(C)c1cc(O)ccc1C=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 4/20 0.55
ALDH1A1 P00352 4/20 0.55
ALOX15 P16050 2/20 0.55
MIF P14174 2/20 0.55
LMNA P02545 2/20 0.55
NR1I2 O75469 1/20 0.55
CYP2C9 P11712 1/20 0.55
HTT P42858 1/20 0.55
NFE2L2 Q16236 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
GAA P10253 1/20 0.38
CYP1A2 P05177 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ATP2A2 P16615 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ATP2A3 Q93084 1/20 0.38
GABBR2 O75899 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL8605013 0.98 ALDH1A1 (0.53) TYRALDH1A1ALOX15MIFLMNA
Water SCHEMBL8605007 0.98 ALDH1A1 (0.53) TYRALDH1A1ALOX15MIFLMNA
SCHEMBL3430867 0.84 ALDH1A1 (0.50) TYRALDH1A1ALOX15MIFLMNA
SCHEMBL11859946 0.82 TYR (0.40) TYRALDH1A1ALOX15MIFLMNA
SCHEMBL662595 0.80 ALDH1A1 (0.55) TYRALDH1A1ALOX15MIFLMNA
SCHEMBL3718412 0.80 APP (0.51) TYRALDH1A1ALOX15MIFLMNA
SCHEMBL395410 0.78 ALDH1A1 (0.39) ALDH1A1ALOX15NR1I2HSD17B10GAA
SCHEMBL29818708 0.78 ALDH1A1 (0.39) TYRALDH1A1HSD17B10TRIM24TRIM33
SCHEMBL3397203 0.77 MIF (0.58) TYRALDH1A1ALOX15MIFLMNA
SCHEMBL8170612 0.77 MIF (0.58) TYRALDH1A1ALOX15MIFLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4587669-B2 2010-11-24 JP claimed
JP-2005509662-A 2005-04-14 JP claimed
EP-1443915-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES Cutanix Corporation (US) 2004-08-11 EP claimed
US-20030157154-A1 Compositions containing hydroxy aromatic aldehydes and their use in treatments CUTANIX CORPORATION 2003-08-21 US claimed
WO-2003043621-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES CUTANIX CORPORATION (US) 2003-05-30 WO claimed
EP-1443915-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES Cutanix Corporation (US) 2004-08-11 EP disclosed
US-20030157154-A1 Compositions containing hydroxy aromatic aldehydes and their use in treatments CUTANIX CORPORATION 2003-08-21 US disclosed
WO-2003043621-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES CUTANIX CORPORATION (US) 2003-05-30 WO disclosed
EP-0724565-B1 NOVEL SPIN TRAP NITRONYL HINDERED PHENOLS OKLAHOMA MED RES FOUND (US) 1999-08-18 EP disclosed
WO-1998010286-A1 METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS ISIS PHARMACEUTICALS, INC. (US) 1998-03-12 WO disclosed
WO-1998001120-A1 METHOD OF INHIBITING NADPH OXIDASE IDUN PHARMACEUTICALS, INCORPORATED (US) 1998-01-15 WO disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0251408-B1 NOVEL ANTI-INFLAMMATORY AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION THE PROCTER & GAMBLE COMPANY (US) 1991-04-17 EP disclosed
US-5000961-A Tert-butyl derivatives of benzylidenecamphor, process for preparing them, their use as antioxidant agents and cosmetic and pharmaceutical compositions containing them L'OREAL (FR) 1991-03-19 US disclosed
EP-0391644-A2 Aryl-substituted rhodanine derivatives ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed
EP-0389176-A2 Beta-lactams and processes for their preparation Beecham Group p.l.c. (GB) 1990-09-26 EP disclosed
EP-0312122-A1 Tellurazolylidene and tellurazolium dye intermediates EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1989-04-19 EP disclosed
EP-0251408-A1 Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation THE PROCTER & GAMBLE COMPANY (US) 1988-01-07 EP disclosed
EP-0167973-A1 Redox indicators Roche Diagnostics GmbH (DE) 1986-01-15 EP disclosed
US-3953398-A 3,5-DI-TERT-ALKYL-4-HYDROXYCINNAMIC ACID OR ESTER AS STABILIZER THE GOODYEAR TIRE & RUBBER COMPANY (US) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030157154-A1 Compositions containing hydroxy aromatic aldehydes and their use in treatments TYR, HRH1, HRH2 TYR 1/4885ALDH1A1 7/4885ALOX15 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.